Patients
This retrospective, nonrandomized study reviewed the electronic medical
records (EMRs) of 334 advanced NSCLC patients who underwent EGFR-TKI
treatment between 2003 and 2019 at the Tokyo Metropolitan Cancer and
Infectious Diseases Center Komagome Hospital, Japan. The inclusion
criteria were as follows: (1) age >=65 years; (2)
histologically or cytologically confirmed unresectable locally advanced
(stage III), metastatic (stage IV), or recurrent EGFR -mutated
NSCLC; (3) EGFR-TKI (only gefitinib, erlotinib, afatinib, or
osimertinib) administration, either as first-line or as later-line
therapy; and (4) evaluable for concomitant medications at EGFR-TKI
treatment initiation.
We obtained the following baseline characteristics from EMRs: sex; age;
body mass index (BMI); smoking status (Brinkman index = daily number of
cigarettes × years); Eastern Cooperative Oncology Group–Performance
Status (ECOG-PS); Charlson Comorbidities Index (CCI), including NSCLC
itself; and Gustave Roussy Immune Score (GRIm-Score) calculated from
serum albumin levels; lactate dehydrogenase (LDH);
neutrophil-to-lymphocyte ratio (NLR)[28]; histological subtype;EGFR mutation status and subtypes; clinical staging (UICC Tumor,
Node, Metastasis [TNM] Classification of Malignant Tumors,
8th edition)[29]; number of organs involved in
metastasis; lines of EGFR-TKI treatment; and concomitant
medications.